An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD + levels in healthy volunteers
Lixisentaide is a GLP-1 drug that was approved in the United States in 2016 and discontinued by its manufacturer (Sanofi) in 2023
Sustainable weight loss and metabolic optimization require a systems-based approach that addresses: Hormonal balance Nutrient deficiencies Gut health Inflammation Hormone Replacement Therapy (HRT) Hormonal imbalancesparticularly low testosterone in men and estrogen/progesterone imbalances in womensignificantly impair metabolic health, muscle preservation, and fat loss
Hormone levels, estrogen balance, treatment protocols, sleep quality, and overall health can all play a role
A faster escalation can mean quicker results but higher risk of nausea, vomiting, and diarrhea